The evolution of antimicrobial peptide resistance in Pseudomonas aeruginosa is shaped by strong epistatic interactions

Nature Communications

Volumn 7, Issue , 2016, Pages

  Jochumsen, Nicholas ^a   Marvig, Rasmus L ^a,b   Damkiær, Søren ^a   Jensen, Rune Lyngklip ^a   Paulander, Wilhelm ^c   Molin, Søren ^a   Jelsbak, Lars ^a   Folkesson, Anders ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b Rigshospital   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; ANTIMICROBIAL CATIONIC PEPTIDE; PEPTIDE;

ANTIMICROBIAL ACTIVITY; BACTERIUM; EPISTASIS; GENETIC ANALYSIS; GENOME; MUTATION; PEPTIDE; PHENOTYPE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENETICS; BACTERIAL GENOME; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLONAL EVOLUTION; CONTROLLED STUDY; CYSTIC FIBROSIS; EPISTASIS; GENE INTERACTION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENOME ANALYSIS; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EVOLUTION; MOLECULAR PHYLOGENY; NONHUMAN; PHENOTYPE; PSEUDOMONAS AERUGINOSA; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; ALLELE; CHEMISTRY; DNA MUTATIONAL ANALYSIS; ESCHERICHIA COLI; FUNGAL GENOME; GENETICS; METABOLISM; MICROBIOLOGY; MUTATION;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

ALLELES; ANTIMICROBIAL CATIONIC PEPTIDES; COLISTIN; CYSTIC FIBROSIS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, BACTERIAL; EPISTASIS, GENETIC; ESCHERICHIA COLI; EVOLUTION, MOLECULAR; GENOME, FUNGAL; MUTATION; PEPTIDES; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSEUDOMONAS AERUGINOSA;

EID: 84989868142     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13002     Document Type: Article

References (56)

1. Abraham, E. P. & Chain, E. An enzyme from bacteria able to destroy penicillin. Nature 146, 837-837 (1940).
2. Silver, L. L. & Bostian, K. A. Discovery and development of new antibiotics: the problem of antibiotic resistance. Antimicrob. Agents Chemother. 37, 377-383 (1993).
3. Silver, L. L. Multi-targeting by monotherapeutic antibacterials. Nat. Rev. Drug. Discov. 6, 41-55 (2007).
4. Mainardi, J. L., Villet, R., Bugg, T. D., Mayer, C. & Arthur, M. Evolution of peptidoglycan biosynthesis under the selective pressure of antibiotics in Gram-positive bacteria. FEMS Microbiol. Rev. 32, 386-408 (2008).
5. Dame, J. B. & Shapiro, B. M. Lipid and lipopolysaccharide composition of Escherichia coli surface-altered mutants selected for resistance to levallorphan, tetracaine, and polymyxin. J. Bacteriol. 137, 1043-1047 (1979).
6. Vaara, M. et al. Characterization of the lipopolysaccharide from the polymyxinresistant pmrA mutants of Salmonella typhimurium. FEBS Lett. 129, 145-149 (1981).
7. Hegreness, M., Shoresh, N., Damian, D., Hartl, D. & Kishony, R. Accelerated evolution of resistance in multidrug environments. Proc. Natl Acad. Sci. USA 105, 13977-13981 (2008).
8. Lozovsky, E. R. et al. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc. Natl Acad. Sci. USA 106, 12025-12030 (2009).
9. Weinreich, D. M., Delaney, N. F., Depristo, M. A. & Hartl, D. L. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312, 111-114 (2006).
10. Palmer, A. C. et al. Delayed commitment to evolutionary fate in antibiotic resistance fitness landscapes. Nat. Commun. 6, 7385 (2015).
11. Toprak, E. et al. Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nat. Genet. 44, 101-105 (2012).
12. Frederiksen, B., Koch, C. & Hoiby, N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 23, 330-335 (1997).
13. Hoeprich, P. D. The polymyxins. Med. Clin. North Am. 54, 1257-1265 (1970).
14. Littlewood, J. M., Miller, M. G., Ghoneim, A. T. & Ramsden, C. H. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet 1, 865 (1985).
15. Storm, D. R., Rosenthal, K. S. & Swanson, P. E. Polymyxin and related peptide antibiotics. Annu. Rev. Biochem. 46, 723-763 (1977).
16. Li, J. et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6, 589-601 (2006).
17. Olaitan, A. O., Morand, S. & Rolain, J. M. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front. Microbiol. 5, 643 (2014).
18. Gutu, A. D. et al. Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems. Antimicrob. Agents Chemother. 57, 2204-2215 (2013).
19. Moskowitz, S. M. et al. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients. Antimicrob. Agents Chemother. 56, 1019-1030 (2012).
20. Gutu, A. D., Rodgers, N. S., Park, J. & Moskowitz, S. M. Pseudomonas aeruginosa high-level resistance to polymyxins and other antimicrobial peptides requires cprA, a gene that is disrupted in the PAO1 strain. Antimicrob. Agents Chemother. 59, 5377-5387 (2015).
21. Conrad, R. S. & Galanos, C. Fatty acid alterations and polymyxin B binding by lipopolysaccharides from Pseudomonas aeruginosa adapted to polymyxin B resistance. Antimicrob. Agents Chemother. 33, 1724-1728 (1989).
22. Ernst, R. K. et al. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 286, 1561-1565 (1999).
23. McPhee, J. B., Lewenza, S. & Hancock, R. E. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol. Microbiol. 50, 205-217 (2003).
24. Moskowitz, S. M., Ernst, R. K. & Miller, S. I. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J. Bacteriol. 186, 575-579 (2004).
25. Fernandez, L. et al. Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel twocomponent regulatory system ParR-ParS. Antimicrob. Agents Chemother. 54, 3372-3382 (2010).
26. Fernandez, L. et al. The two-component system CprRS senses cationic peptides and triggers adaptive resistance in Pseudomonas aeruginosa independently of ParRS. Antimicrob. Agents Chemother. 56, 6212-6222 (2012).
27. Bialvaei, A. Z. & Samadi Kafil, H. Colistin, mechanisms and prevalence of resistance. Curr. Med. Res. Opin. 31, 707-721 (2015).
28. Macfarlane, E. L., Kwasnicka, A. & Hancock, R. E. Role of Pseudomonas aeruginosa PhoP-PhoQ in resistance to antimicrobial cationic peptides and aminoglycosides. Microbiology 146, 2543-2554 (2000).
29. Johansen, H. K., Moskowitz, S. M., Ciofu, O., Pressler, T. & Hoiby, N. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J. Cyst. Fibros. 7, 391-397 (2008).
30. Miller, A. K. et al. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob. Agents Chemother. 55, 5761-5769 (2011).
31. Marvig, R. L. et al. Draft genome sequences of Pseudomonas aeruginosa B3 strains isolated from a cystic fibrosis patient undergoing antibiotic chemotherapy. Genome Announc. 1, 00804-00813 (2013).
32. Yang, L. et al. Evolutionary dynamics of bacteria in a human host environment. Proc. Natl Acad. Sci. USA 108, 7481-7486 (2011).
33. Ritchings, B. W., Almira, E. C., Lory, S. & Ramphal, R. Cloning and phenotypic characterization of fleS and fleR, new response regulators of Pseudomonas aeruginosa which regulate motility and adhesion to mucin. Infect. Immun. 63, 4868-4876 (1995).
34. Palmer, A. C. & Kishony, R. Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance. Nat. Rev. Genet. 14, 243-248 (2013).
35. Damkiaer, S., Yang, L., Molin, S. & Jelsbak, L. Evolutionary remodeling of global regulatory networks during long-term bacterial adaptation to human hosts. Proc. Natl Acad. Sci. USA 110, 7766-7771 (2013).
36. Lind, P. A., Farr, A. D. & Rainey, P. B. Experimental evolution reveals hidden diversity in evolutionary pathways. Elife 4, 07074 (2015).
37. Blount, Z. D., Barrick, J. E., Davidson, C. J. & Lenski, R. E. Genomic analysis of a key innovation in an experimental Escherichia coli population. Nature 489, 513-518 (2012).
38. Lee, J. Y., Park, Y. K., Chung, E. S., Na, I. Y. & Ko, K. S. Evolved resistance to colistin and its loss due to genetic reversion in Pseudomonas aeruginosa. Sci. Rep. 6, 25543 (2016).
39. Jochumsen, N., Liu, Y., Molin, S. & Folkesson, A. A Mig-14-like protein (PA5003) affects antimicrobial peptide recognition in Pseudomonas aeruginosa. Microbiology 157, 2647-2657 (2011).
40. Owusu-Anim, D. & Kwon, D. H. Differential role of two-component regulatory systems (phoPQ and pmrAB) in polymyxin B susceptibility of Pseudomonas aeruginosa. Adv. Microbiol. 2, 31-36 (2012).
41. Barrow, K. & Kwon, D. H. Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53, 5150-5154 (2009).
42. Mdluli, K. E. et al. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50, 2178-2184 (2006).
43. Tashiro, Y. et al. Opr86 is essential for viability and is a potential candidate for a protective antigen against biofilm formation by Pseudomonas aeruginosa. J. Bacteriol. 190, 3969-3978 (2008).
44. Marvig, R. L., Johansen, H. K., Molin, S. & Jelsbak, L. Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators. PLOS Genet. 9, e1003741 (2013).
45. Marvig, R. L., Sommer, L. M., Molin, S. & Johansen, H. K. Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis. Nat. Genet. 47, 57-64 (2015).
46. Fothergill, J. L., Neill, D. R., Loman, N., Winstanley, C. & Kadioglu, A. Pseudomonas aeruginosa adaptation in the nasopharyngeal reservoir leads to migration and persistence in the lungs. Nat. Commun. 5, 4780 (2014).
47. Applebee, M. K., Herrgard, M. J. & Palsson, B. O. Impact of individual mutations on increased fitness in adaptively evolved strains of Escherichia coli. J. Bacteriol. 190, 5087-5094 (2008).
48. Chou, H. H., Chiu, H. C., Delaney, N. F., Segre, D. & Marx, C. J. Diminishing returns epistasis among beneficial mutations decelerates adaptation. Science 332, 1190-1192 (2011).
49. Khan, A. I., Dinh, D. M., Schneider, D., Lenski, R. E. & Cooper, T. F. Negative epistasis between beneficial mutations in an evolving bacterial population. Science 332, 1193-1196 (2011).
50. Sanjuan, R., Moya, A. & Elena, S. F. The contribution of epistasis to the architecture of fitness in an RNA virus. Proc. Natl Acad. Sci. USA 101, 15376-15379 (2004).
51. Wiegand, I., Hilpert, K. & Hancock, R. E. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 3, 163-175 (2008).
52. Ausubel, F. M. et al. Current Protocols in Molecular Biology (John Wiley, 1996).
53. Choi, K. H. & Schweizer, H. P. An improved method for rapid generation of unmarked Pseudomonas aeruginosa deletion mutants. BMC Microbiol. 5, 30 (2005).
54. Krawitz, P. et al. Microindel detection in short-read sequence data. Bioinformatics 26, 722-729 (2010).
55. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491-498 (2011).
56. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).